Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06900153

Parenting and CAH - 21-hydroxylase Deficiency

Congenital adrenal hyperplasia (CAH) is a genetic disease with autosomal recessive transmission, which is defined by a deficiency of one of the steroidogenesis enzymes. 21-hydroxylase deficiency (21OHD), related to mutations of the CYP21A2 gene, is involved in 90 to 95% of CAH cases. Depending on the severity of the mutations of this gene, there are severe forms known as "classic" (FC), with neonatal onset, and moderate forms known as "non-classic" (FNC), with onset later in childhood or after puberty. The classic form includes the salt-wasting form and the pure virilizing form, depending on the degree of aldosterone deficiency. The sexuality and fertility of women with classic 21OHD deficiency are impaired by several factors such as disruption of the gonadotropic axis due to overproduction of androgens and progesterone by the adrenal glands, and mechanical and psychological factors related to genital surgery. The fertility of these women improves over time, largely due to earlier treatment of CAH, improved therapeutic compliance and surgical advances in genital reconstruction leading to an increase in the percentage of patients who are sexually active. However, there is little data available, and even less on the course of pregnancy, its complications and its outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 or over
  • Patients with HCS due to 21-hydroxylase deficiency, confirmed genetically
  • Patients who have been informed and do not object to participating in the research

Exclusion criteria

  • Patients who do not speak French
  • Patients who are not affiliated to a social security scheme or who are not entitled to it
  • Patients under legal protection, or under guardianship or trusteeship.

Treatment and study plan

Phone questionnaire

Other

the investigator calls the patient and asks her questions about her parental project and her pregnancies

Primary outcomes

  1. to describe how pregnancies are achieved: spontaneous or induced, if induced by which ART technique.

    Time frame: Day 1

    Information on how the pregnancy was achieved will be collected from the medical file and will be supplemented on the day of inclusion by a telephone questionnaire to the patient

Secondary outcomes

  1. Describe the existence of a parental project among the women in the cohort

    Time frame: Day 1

    The description of the parental project will be based on the patients' declaration of the presence or absence of a desire to have children, and if not, what the reasons were

  2. Describe obstetric complications

    Time frame: Day 1

    The description of obstetrical complications (GEU, miscarriages, in utero fetal death, IUGR, gestational diabetes, hypertension, pre-eclampsia, HELLP syndrome, cholestasis gravidarum, term of delivery, spontaneous or induced labor, birth weight, breastfeeding if desired) will be based on data from pregnancy and childbirth follow-up reports.

  3. Describe the hormonal substitution adjustments.

    Time frame: Day 1

    The description of hormone replacement adjustments will be based on the prescription of Hydrocortisone and Fludrocortisone.

Study contacts

Contact information is provided by the study sponsor or research team.

Anne BACHELOT

CONTACT

[email protected]

01 42 16 02 46

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Official study title

Description of Parental Projects, Pregnancies and Pregnancy Outcomes in Patients With a Classic Form of 21-hydroxylase Deficiency

Acronym: PARENT-HCS

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 28, 2025
Registry last updated
Mar 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.